How did CPHI's Q3 earnings compare to previous quarters?

China Pharma Holdings (CPHI) experienced a decline in net income and revenue from the previous quarter in Q3, with net income dropping to -$1.22 million and revenue decreasing to $1.1 million: 1. **Significant Decrease in Net Income**: The net income in Q3 was -$1.22 million, which is a substantial decrease from the previous quarter's net income of -$955,892. This indicates a worsening financial performance in terms of profitability. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |CPHI|CPHI.A|China Pharma Holdings|2024 Q1|-100.82777282888213|-955892|170| |CPHI|CPHI.A|China Pharma Holdings|2024 Q2|-142.50584710022613|-1438130|170| |CPHI|CPHI.A|China Pharma Holdings|2024 Q3|-43.764274691358025|-1117911|170| |CPHI|CPHI.A|China Pharma Holdings|2024 Q4|0.6314655015001465|-1224432|170| 2. **Decline in Total Revenue**: The total revenue for Q3 was $1.1 million, down from the previous quarter's revenue of $1.13 million. This suggests a reduction in the company's sales or income-generating activities. The company's financial performance appears to be under pressure, with both net income and revenue experiencing notable declines compared to the previous quarter.